Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B : Remodeling of Antiviral and Regulatory Mediators-Reference-Cited by-同舟云学术

Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B : Remodeling of Antiviral and Regulatory Mediators

Published:2021-06-20 Issue:1 Volume:74 Page:55-71
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Amin Oliver E.¹^ORCID,Colbeck Emily J.¹,Daffis Stephane²,Khan Shahzada²,Ramakrishnan Dhivya²,Pattabiraman Divya²,Chu Ruth²,Micolochick Steuer Holly²,Lehar Sophie²,Peiser Leanne²,Palazzo Adam²,Frey Christian²,Davies Jessica¹,Javanbakht Hassan²,Rosenberg William M.C.³,Fletcher Simon P.²^ORCID,Maini Mala K.¹^ORCID,Pallett Laura J.¹^ORCID

Affiliation:

1. Division of Infection & Immunity Institute of Immunity & Transplantation University College London London United Kingdom

2. Gilead Sciences Inc. Foster City CA

3. Institute for Liver and Digestive Health University College London London United Kingdom

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31695

Reference55 articles.

1. World Health Organization Global Hepatitis Programme.Global hepatitis report.2017.http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455‐eng.pdf?ua=1. Accessed May 21 2020.

2. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

3. HBV cure: why, how, when?

4. Adaptive immunity in HBV infection

5. Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of 1-(indolin-1-yl)-2-(thiazol-2-yl)ethan-1-one derivatives as novel anti-HBV agent with potential TLR7-agonistic effect;European Journal of Medicinal Chemistry;2024-09

2. Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: ‘Progress toward hepatitis B elimination in Canada’;Canadian Liver Journal;2024-08-28

3. Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus;Gut;2024-07-05

4. Current trends and advances in antiviral therapy for chronic hepatitis B;Chinese Medical Journal;2024-06-28

5. Pharmacological activation of TLR7 exerts inhibition on the replication of EV-D68 in respiratory cells;Journal of Virology;2024-06-13